BioWorld

April 22, 2003

Changing CytRx Licenses Broad RNAi Technology From U-Mass

CytRx Corp. is changing by taking up the torch of RNA interference technology through license agreements with the University of Massachusetts Medical School. (BioWorld Today) Read More

Drug Delivery Firm Acusphere Raises $20M In Eighth Round

Drop-Out Deciduous Baby Teeth Find New Life Careers In Hitherto Unexpected Postnatal Stem Cells

Structural GenomiX Installing Platform As Part Of Lilly Alliance

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...